Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Immune Checkpoint Inhibitors (ICIs) & Pseudoprogression

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Immune Checkpoint Inhibitors can induce pseudoprogression, not accompanied by clinical deterioration
Billan et al. 2020 The Lancet Oncology 21: e463-e476

Immune Checkpoint Inhibitors can induce hyperprogression (ie, rapid progression of the disease as a result of immunotherapy
Billan et al. 2020 The Lancet Oncology 21: e463-e476

Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy
Failing et al. 2019
Review
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy
Parseghian et al. 2018 J Immunotherapy 41: 284-291
Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
Adashek et al. 2020a
Review
Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature
Grecea et al. 2020
Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review
Michalarea et al. 2019 Current Problems in Cancer 43: 487
Treatment after progression in the era of immunotherapy
Billan et al. 2020 The Lancet Oncology 21: e463-e476
Review

7/1/2026